Menu
LAUSANNE, Switzerland, 9 March 2017: Sophia Genetics, global leader in Data-Driven Medicine, announced today, at the 2017 Wired Health Conference in London, that by the end of Q1 2017 the company will officially cross the strategic threshold of analyzing genomic profiles from 100K patients with its artificial intelligence SOPHiA.
Speaking on the main stage of the 2017 Wired Health Conference about the company’s innovative approach to democratize Data-Driven Medicine, Jurgi Camblong, Sophia Genetics’ CEO, also confirmed that the company has reached the strategic milestones of 250 health institutions using its AI technology SOPHiA in 45 countries, further strengthening SOPHiA’s leading position as the most used technology for Data-Driven Medicine worldwide.
The AI of the Swiss-based healthtech company, which counts Illumina amongst its partners, is used by hospitals to overcome the bottleneck of analyzing the complex data generated by genome sequencing. Used by hospitals across 45 countries, SOPHiA is continually trained by its global network of users to identify key variants in patients’ genomic profiles and turn this information into actionable insights, helping clinicians make informed decisions.
Interpretation of genomics data has for long been lengthy, costly, inaccurate and treated like an art. But Sophia Genetics has managed to make genomic analysis accessible, standardized and accurate, to support a global network of 250 institutions to pool patients’ genomic data into its unique SaaS analytics platform powered by SOPHiA. With the company AI, hospitals get first-hand actionable insights to understand the molecular causes behind diseases in oncology, hereditary cancer, cardiology, metabolism and pediatric conditions.
The more data SOPHiA processes, the more it learns, as information is continuously shared anonymously on the platform to help clinicians advance their own knowledge and make better decisions. In an ever-evolving field, where expertise might be sitting in different places across the globe, knowledge sharing is key to ensure that the expertise of a specialist in London for instance can be accessed to save patients somewhere else on the planet.
Since its inception, the rapid adoption of SOPHiA has triggered a wave of democratization of Data-Driven Medicine worldwide by empowering hospitals across the globe to rapidly embrace the genomics revolution. Now used by over 250 hospitals in 45 countries, SOPHiA allows any hospital, no matter its experience in genomics, to get up to speed and analyze genomic data to identify disease-causing variants and match them with the most effective drugs that can be used to treat patients.
Founded in 2011, Sophia Genetics has since been at the forefront of standardizing genomic data analysis for clinical diagnostics. The company is currently enrolling 10 new healthcare institutions every month on its SaaS analytics platform powered by SOPHiA. In the summer 2016, Sophia Genetics began global expansion outside Europe, which resulted in the adoption of its AI solution by leading hospitals and healthcare institutions from Canada, Australia, Russia, and Latin America. Most recently, thanks to its accessibility, SOPHiA has also been deployed by hospitals from the African continent, further democratizing patients’ access to Data-Driven Medicine.
Speaking about the benefits of using SOPHiA in the clinical workflow, Dr. Reinhard Hiller from the South African Centre for Proteomic and Genomic Research (CPGR) commented: “In creating a first-of-its-kind Genomic Medicine offering in Africa, working with Sophia Genetics’ platform has been beneficial because its implementation requires a stringent certification program, it provides high-quality reference samples for workflow validation, and, its analysis and reporting algorithms have been extensively tested by a global community of Genomic Medicine practitioners, allowing us to offer a best-in-class service from the word go.”
Prof. Hicham Mansour, Geneticist, Al Azhar Oncology Center, Genetic Department - University Mohamed 1st, added: “Using the artificial intelligence developed by Sophia Genetics allows us to analyze our genomic data quickly and with great confidence, to better diagnose and follow up with our patients”.
Addressing the company’s strategic milestones announced today, Sophia Genetics’ CEO Jurgi Camblong declared from the 2017 Wired Health Conference in London: “As the industry is approaching the $100 genome, Sophia Genetics will cross by the end of Q1 2017 the strategic threshold of 100K patients’ genomic profiles analyzed, showing that SOPHiA is now clinicians’ technology of choice for addressing the challenges of analyzing the tsunami of genomics data generated by the modern clinical workflow. By bringing down this barrier, SOPHiA allows hospitals worldwide to embrace the clinical genomics revolution, to the ultimate benefits of patients.”
Jurgi Camblong added: “Those key milestones are only the beginning of the global movement to bring Data-Driven Medicine to all. Sophia Genetics is constantly improving its technology and operations with the goal of making actionable clinical information accessible to all. I am particularly proud to bring our technology to Africa. The company’s growth and momentum to date shows that our goal to democratize Data-Driven Medicine is well under way”.
LAUSANNE, Switzerland, 13 February 2016 – Sophia Genetics, global leader in Data-Driven Medicine, announced today that ten new genomic institutions from Latin America have started using SOPHiA - the company’s AI - to democratize access to clinical genomics on the continent, and improve patient diagnosis and care.
Using the Sophia DDM® advanced SaaS analytics platform for clinical genomics, the institutions will first deploy SOPHiA for hereditary cancer diagnosis. About 1.1 million new cancer cases and 600,000 cancer deaths are estimated to occur annually in Latin America and the Caribbean[1]. Hereditary cancer predisposition syndromes comprise approximately 10% of diagnosed cancers but familial forms are believed to account for up to 30% of some cancers. In the Hispanic population, the most commonly diagnosed hereditary cancers include colorectal cancer syndromes, such as Lynch Syndrome, Familial Adenomatous Polyposis, and hereditary breast and ovarian cancers, which can all be diagnosed using SOPHiA.
In this context, SOPHiA will help leverage genomic data to improve and accelerate patient diagnosis and care. The increased use of SOPHiA in Latin America will also ensure that the highest standard of genomic testing is provided to all patients in need, and that they have access to the latest advances in the detection of hereditary cancers. Following a first partnership announced in October 2016 with DASA, the largest medical diagnostic company in Latin America, SOPHiA has been rapidly adopted in the region for its superiority and ease of use to obtain actionable insights from genomic data and improve patient care.
Latest genomic institutions to adopt SOPHiA in Latin America:
· In Mexico, Servicios Genomicos, a spinoff from INMEGEN (Mexico’s National Genomic Medicine Institute), a predominant actor in clinical genomics, will use SOPHiA to better diagnose hereditary cancer predispositions, develop preventive medicine and design treatments tailored to patient’s genetic makeup. Dr. Carmen Aláez Versón, Chief of the Genomic Diagnosis Laboratory at Servicios Genomicos commented “Sophia Genetics first helped us quickly overcome the burden and complexity of a complete validation program to obtain consistently reliable top quality data. We then saw in Sophia DDM®'s friendly interface, a decisive tool in optimizing the data analysis and interpretation of our growing patient database.”
· In Colombia, SOPHiA will be used by GenCell Pharma, a national pioneer in molecular diagnostics, to offer genomic profiling to patients at risk of hereditary cancers. Andres Zapata, Director of GenCell commented: “Offering the best in class diagnostic grade sequencing reports to our patients from Colombia and LATAM is our goal at GenCell. Through Sophia Genetics we saw the best partner to efficiently and confidently implement such technology. The access to data pooling information from the community through Sophia DDM® analytical platform is crucial to help us better diagnose patients.”
· In Uruguay, Genia is one of the major regional actors in clinical genomics. They will use SOPHiA to analyse the genetic makeup of patients from the five countries of the Southern Cone, and produce the relevant diagnoses. Juan Martín Marqués scientific director at Genia commented: “Thanks to the superior results obtained by SOPHiA on previously hard to find genetic alterations for BRCA1/2 and the easiness to detect all these variants in one complete simple workflow, we have decided to implement Sophia DDM® in routine for all of our samples.”
SOPHiA is currently used by 240 healthcare institutions from 39 countries. In Latin America the AI will gradually be deployed further in oncology, metabolism, paediatrics and cardiology. Thanks to its Sophia DDM® platform which scales the world-class expertise of its clinical genomics community and provides online secure access to genomic analysis, Sophia Genetics allows any institution, no matter their experience in Next Generation Sequencing, to embrace the advances of the genomic revolution, ensuring no patient misses out.
Jurgi Camblong, CEO and co-founder of Sophia Genetics commented: “By continuing to deploy SOPHiA globally we are democratizing access to the world’s most advanced technology for clinical genomics. In Latin America, SOPHiA will help speed up diagnosis and treatment, and provide the highest standard of genomic testing to all patients in need.”
[1] The Cancer Atlas, 2017
CE-IVD marking recognises Sophia Genetics Hereditary Cancer Solution unmatched performance, the first of its kind to allow for the diagnosis of hereditary breast, ovarian and digestive cancers
SAN FRANSISCO, USA – 11 January 2016: Sophia Genetics, global leader in Data-Driven Medicine, announced today, from the 35th Annual J.P. Morgan Healthcare Conference, the CE-IVD marking of its Hereditary Cancer Solution. A simple and fast procedure for healthcare professionals engaged in clinical diagnostics, Sophia Genetics Hereditary Cancer Solution helps quickly screen the 27 most relevant genes associated with hereditary cancer. It is the first solution CE-IVD marked that allows for the diagnosis of hereditary breast, ovarian and digestive cancers.
The CE-IVD certification applies to both the kit (IDT’s xGen® Lockdown® Probe target capture technology) and the analytics, which together make up Sophia Genetics’ Hereditary Cancer Solution. This joint certification makes the Hereditary Cancer Solution the only product of its kind to be CE-IVD marked. This powerful mix ensures SOPHiA, Sophia Genetics AI, is fuelled with high quality data to deliver unmatched analytical performance for the detection of genomic mutations responsible for hereditary breast and ovarian cancer, lynch syndrome, intestinal polyposis syndrome and familial adenomatous polyposis.
Early genomic testing can help identify an increased risk of particular types of cancer due to gene variants passed on from parent to child. Sophia Genetics’ CE-IVD marked Hereditary Cancer Solution will thus help clinicians with patient counselling, allowing them to suggest appropriate lifestyle changes, encourage regular cancer screening for early detection, prescribe medicines to reduce disease risk, or recommend risk reducing surgery.
Reacting to this achievement for target capture–based technology, Dr. Joseph Walder, Founder of IDT, said “We are excited that xGen® Lockdown® Probes have contributed to Sophia Genetics Hereditary Cancer Solution being granted a CE-IVD mark. This represents a major step in IDT’s support for the diagnostics community with robust reagents that facilitate early and accurate detection of disease risk through genomic testing, and demonstrates our commitment to driving advances in genetics and medicine.”
Commenting on this joint certification making the Hereditary Cancer Solution the only product of its kind to be CE-IVD marked, Jurgi Camblong, CEO and Co-Founder of Sophia Genetics, concluded: “The CE-IVD marking of our Hereditary Cancer Solution illustrates our continued efforts to ensure the best accuracy in genomic testing, and is another milestone on our journey towards the democratisation of Data-Driven Medicine.”
Sophia Genetics raises the bar in secure high speed genomic data flows worldwide with new privacy technology for the compression, storage, and access to genomic data which paves the way to a new industry standard
LAUSANNE, Switzerland – 06 December 2016: Sophia Genetics, global leader in Data-Driven Medicine, unveiled today a new privacy-protecting technology for the storage and access to patients’ genomic information worldwide, paving the way to a new industry standard. The largest clinical genomics platform – 215 hospitals from 35 countries connected - and the designer of SOPHiA, the most advanced artificial intelligence for Data-Driven Medicine, Sophia Genetics decided to leverage its leadership position in genomics to ensure the secure democratization of Data-Driven Medicine worldwide.
Developed with genomic data privacy and security experts from the Swiss Federal Institute of Technology Lausanne (EPFL), and biomedical researchers from Stanford University, the new technology unveiled today makes sure the privacy of genomic information is not compromised as patients’ data go through various processing steps, from compression to storage and finally access by healthcare institutions. A true revolution both for patients and the healthcare community, the new privacy-preserving technology paves the way to a new industry standard and has been highlighted in Genome Research, an international, peer-reviewed genome sciences journal, in a publication entitled A Privacy-Preserving Solution for Compressed Storage and Selective Retrieval of Genomic Data.
Adam Molyneaux, Chief Information Officer at Sophia Genetics declares “Privacy has become an increasingly serious concern given both the highly personal nature of genomic information, and the increasing number of requests for access to patients’ genomic information generated by healthcare institutions all along patients’ life. Preventing unsolicited use of personal data requires to not only encrypt data but also to define data access privileges, enabling selective retrieval of genomic data.”
The new genomic data privacy technology presented today also tackles another big challenge of the Data-Driven Medicine revolution: genomic data costs of storage. Adam Molyneaux explains “The data of one human genome can go from 30 GB to 200 GB. And with new high speed DNA sequencing technologies driving costs of generating genomic data down, the growth rate of genomic data has more than doubled each year since 2007, outpacing Moore’s law. Over 100 petabytes of storage are already used by the world’s largest 20 biological research institutions, which corresponds to more than $1 million USD in storage maintenance costs every month.”
Jean-Pierre Hubaux, Professor at EPFL and senior author of the publication, commented “This new technology offers an effective space-saving and privacy-preserving solution for the storage of clinical genomic data. The currently available solutions were developed before the widespread usage of high-throughput technologies and do not consider effective protection when compressing genomic sequences; the current standard saves 34% storage on average in lossless compression. Our no-compromise solution uses 18% less storage while allowing for unprecedented levels of security in genomic data storage as well as selective retrieval.”
Presenting the new solution today, Jurgi Camblong, Sophia Genetics’ CEO and co-founder, declared “As the global leader in Data-Driven Medicine, we are at the forefront of clinical genomics, and committed to developing new standards to tackle the challenges posed by the democratisation of Data-Driven Medicine. I am proud that, in partnership with EPFL, we are raising the bar in genomic data privacy and at the same time lowering the cost of storage of genomic data. This is a necessary contribution to our field for the large-scale application of personal genomics in research and clinical settings.”
Nick-named SECRAM[1], the new space-saving and privacy-preserving technology for the storage of clinical genomic data has been made accessible to the whole genomics community in open source at https://github.com/acs6610987/secram.
LAUSANNE, Switzerland and Cambridge, UK – 17 November 2016: Sophia Genetics, the global leader in Data-Driven Medicine, and Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world-leader in the application of gene editing technologies, today announced they have entered into a new partnership to improve the quality of Next Generation Sequencing (NGS) based genetic testing in oncology patient samples.
Under the terms of the agreement, Horizon’s HDx™ Reference Standards will be combined with Sophia Genetics’ artificial intelligence, providing hospitals and laboratories with more accurate and high quality NGS testing services, assays and genomic data analysis.
In particular, current and future users of the Sophia DDM® analytical platform will be able to assess the quality of their NGS assays, reaching the highest levels of sensitivity and specificity. The use of HDx Reference Standards will help with performance monitoring as well as reproducibility and repeatability of NGS tests.
Jurgi Camblong, Chief Executive Officer and co-founder, Sophia Genetics, commented: “The quality of molecular profiling is a cornerstone of NGS testing and relies on a series of technical steps being performed correctly, from the collection of patient samples and DNA extraction, to creating and analysing genomic data. Sophia Genetics is helping hospitals and laboratories to make the most of their NGS testing and we are delighted to be combining Horizon’s Reference Standards with our artificial intelligence for Data-Driven Medicine, increasing the number of patients that will benefit from reliable NGS genomic testing results.”
Dr. Darrin M. Disley, Chief Executive Officer, Horizon Discovery Group, commented: “Our new partnership with Sophia Genetics demonstrates the increasingly important role well validated controls have in the provision of molecular assays, especially for complex technologies such as NGS as they become more widely adopted. We look forward to working closely with Sophia Genetics as our Reference Standards become an important component of their workflows.”
Financial terms for the partnership have not been disclosed.
ntegration of QIASeq FX DNA library prep into Sophia DDM® analytical platform enables superior genomic variants detection in clinical diagnostics
LAUSANNE, Switzerland – 11 November 2016 – Today, at the AMP 2016 Annual Meeting, Sophia Genetics, the global leader in Data-Driven Medicine, announced a new partnership with QIAGEN to further democratize Data-Driven Medicine. The partnership includes the integration of QIAGEN QIAseq FX, one of the most advanced library preparation technologies in the market to date, with Sophia DDM® analytical platform to enable superior detection of genomic variants in clinical diagnostics.
Sophia Genetics partnership with QIAGEN will further facilitate the use of capture technologies and ensure its users get the most out of SOPHiA™ artificial intelligence for the detection of variants in challenging genomic regions. Financial terms were not disclosed.
The collaboration between the two companies will benefit hospitals and laboratories which will get fully validated library kits and capture-based gene panels, providing patients with state-of-the-art genomic testing and faster, easier and more accurate results in routine clinical diagnostics. This partnership follows another agreement Sophia Genetics signed in February 2016 with Integrated DNA Technologies (IDT), which increased the adoption of capture-based technologies for routine clinical diagnostics by its community.
Jurgi Camblong, CEO and co-founder of Sophia Genetics commented “We are very pleased to broaden our offering with this new partnership. Through this collaboration, our fast-growing community of hospitals and laboratories will benefit from QIAGEN’s reliable and high-quality products to obtain clinical-grade results on our analytical platform Sophia DDM®, eventually bringing improved diagnostics and treatment options to patients.”
Colin Baron, Senior Director, Head of Product Management, NGS Life Sciences, QIAGEN, added “We are very excited to partner with Sophia Genetics. We are pleased by this further demonstration that QIAGEN technologies are significantly improving the quality of next-generation sequencing results”.
This partnership launches worldwide, allowing laboratories to immediately get improved throughput, reduced hands-on time and more reliable results of genomic tests.
Hospitals and laboratories using the Sophia DDM® analytical platform in 35 countries will benefit from SOPHiA™ artificial intelligence combined with Archer® FusionPlex®, VariantPlex™, and Reveal ctDNA™ sample preparation kits
LAUSANNE, Switzerland – 10 November 2016 – Today, at the AMP 2016 Annual Meeting, Sophia Genetics, global leader in Data-Driven Medicine, and world-class Next-Generation Sequencing (NGS) assay developer ArcherDX, announced the signing of a new partnership to combine their technological solutions. The partnership will focus on oncology solutions addressing solid tumours and haematological disorders, as well as applications in liquid biopsy and immune repertoire profiling.
The agreement sees Sophia Genetics integrate the ArcherDX portfolio of NGS test kits into the Sophia DDM® analytical platform and offer the combined solutions to its ever-expanding network of hospitals and laboratories around the world. This partnership provides Sophia DDM® users with the unique experience of SOPHiA™ artificial intelligence making the most out of research samples prepared with ArcherDX sample preparation assays.
Research hospitals and laboratories will benefit not only from comprehensively detecting all kinds of genomic alterations in a single test, such as SNVs, INDELs, CNVs and gene fusions, but also from faster adoption of the solutions in clinical research and superior analytical performance. As more research laboratories use Sophia DDM® and upload sample genomic data, SOPHiA™ will continuously learn, providing ever more accurate and personalised characterizations of genomic alterations and treatments.
Jason Myers, Ph.D., CEO at ArcherDX, said “This exciting partnership with Sophia Genetics will help to decentralize NGS-based testing in molecular laboratories. By joining forces, ArcherDX and Sophia Genetics are enabling international laboratories of all sizes using SOPHiA™ to access and report on cutting-edge applications that ArcherDX has developed, including gene fusions, liquid biopsies, and immune repertoire profiling.”
Through Sophia DDM®, a clinical genomics community of more than 215 laboratories and hospitals in over 35 countries will have the opportunity to use Sophia Genetics and ArcherDX combined solutions to precisely identify disease-associated mutations with advanced genomic tests.
Jurgi Camblong, CEO and co-founder of Sophia Genetics commented “This new partnership allows us to continue building the ecosystem around Sophia DDM®. We’re committed to continuing to help unlock the power of data analysis for our fast-growing clinical genomics community. ArcherDX’s purpose-built technologies for targeted NGS solutions will help SOPHiA™ generate precision results accessible on Sophia DDM®, thus further democratizing Data-Driven Medicine.”
Sophia Genetics’ and ArcherDX’s partnership launches worldwide immediately, helping laboratories transition to NGS, obtain improved throughput, reduce hands-on time and generate reliable results.
LAUSANNE, Switzerland – 11 October 2016 – Sophia Genetics, the global leader in Data Driven Medicine (DDM), announced today that it has entered Latin America as the DASA network of laboratories in LatAm is adopting the company advanced analytical platform Sophia DDM® to facilitate and accelerate patients’ diagnosis, and the selection of appropriate treatments by clinicians. Under the agreement, SOPHiA, Sophia Genetics’ artificial intelligence, will analyse patients’ genomic profiles produced in DASA laboratories to spot pathogenic genetic variants responsible for diseases, and help advise clinicians on best care.
By gaining access to SOPHiA, LatAm clinicians working with DASA will directly benefit from a technology helping them to provide better and faster diagnostics to their patients. They will also have the tools to recommend the most appropriate treatment plans, based on the results of their patients’ genomic tests. As an initial step, DASA will entrust Sophia Genetics with all its so-called “BRCA” and “CFTR” tests, which are genomic tests performed to identify respectively genetic variants in breast cancer susceptibility genes, and related to cystic fibrosis.
DASA - Diagnosticos da America - is the largest medical diagnostic company in Latin America, 5th largest in the world, with 321 branches across Brazil catering for 55,000 patients daily and processing more than 10 million tests each month. It is CAP (College of American Pathologists) certified laboratory and provides more than 3000 types of clinical analyses and diagnostic imaging. Its network accounts more than 500 sample collection service units and 12 central laboratories across Brazil, where analyses are conducted for the LatAm continent. The agreement announced today means that the thousands of patients relying on DASA solutions to be diagnosed through their clinicians will now benefit from better and faster screening of their genomic profiles for pathogenic genetic variants.
Commenting on the importance of SOPHiA availability in LatAm, Pr Eduardo Levi, Consultor em Biologia Molecular, at DASA said “Partnering with Sophia Genetics came as a natural choice as we were looking to strengthen our solutions for molecular diagnostics on the continent. Based on the company success in other regions, and across the 180 members of its clinical genomic community, we knew it would be the best fit for our “BRCA” and “CFTR” tests. We are very happy that LatAm and LatAm patients are now able to join the Data-Driven medicine revolution thanks to Sophia Genetics.”
Sophia Genetics’ CEO and co-founder Jurgi Camblong added “Since its inception, Sophia Genetics’ mission has been to provide patients with access to Data Driven Medicine. With today’s agreement, we are doing just that as a whole new continent will now benefit from better and faster identification of genetic variants responsible for diseases. Moving forward, we will continue to expand our presence worldwide so that more clinicians can use our solutions and more patients can benefit from it. On our journey towards global democratisation of Data Driven Medicine we will also continue to broader our genomics community for molecular diagnostics as more hospitals and laboratories will use our artificial intelligence for molecular diagnosis solutions.”
Sophia Genetics’ clinical genomics community now spans across 31 countries worldwide and gathers 180 healthcare institutions, performing over 5’000 patients’ genomics profile analysis every month.
LAUSANNE, Switzerland - 06 October 2016 – Sophia Genetics, the global leader in Data-Driven Medicine (DDM), today introduced ONCOPORTAL. This new technology digitally matches the unique genomic profile of patient tumours with actionable information on the best available treatments, cancer aggressiveness and relevant ongoing clinical trials. Accessible through the V4.0 of Sophia DDM®, ONCOPORTAL dramatically improves the diagnosis and treatment of solid tumours and haematological malignancies for patients around the world.
Powered by SOPHiA, the most advanced artificial intelligence in Data-Driven Medicine, Sophia DDM® is already being used by 180 leading hospitals in 31 countries to analyse genomics data produced on next generation DNA sequencers. The AI accurately detects and characterises patient-specific alterations for 70 genomic test applications, helping to better diagnose 200 patients daily.
With ONCOPORTAL, Sophia DDM® users now not only detect patient-specific alterations with top analytical performance, but also benefit from actionable information associated with it. In just a few clicks, pathologists and oncologists can access a comprehensive and easy to read report comprising diagnostic and prognosis information about patient tumours, lists of the best associated treatments, the efficacy of relevant drugs, toxicity and adverse events.
When no drugs match a patient’s tumour, the concise actionable report generated on ONCOPORTAL provides easy to consult information about ongoing clinical trials from phase I, II, III and IV corresponding to the tumour’s genomic profile. For patients, this presents new care options that match their unique tumour profile and timely access to the most promising therapeutic options.
Until recently, pathologists and oncologists had to spend precious time sequencing patient tumours genomic profiles. They had to bioinformatically analyse the data to detect genomic alterations and finally undertake a laborious process to identify treatments – with virtually no guarantee that the treatments would fit the patient unique genomic profile. Thanks to ONCOPORTAL, pathologists and oncologists can now access a comprehensive report with all this information in one place and in a standardised and integrated manner just a couple of hours after uploading the raw genomic data on Sophia DDM®.
As users add information and share knowledge on the Sophia DDM® platform, ONCOPORTAL is constantly updated with the latest medical knowledge thanks to machine learning techniques, allowing clinicians to save time and focus on the most complex cases.
Dr Pierre Hutter, CSO and Co-founder at Sophia Genetics said “Tumours result first and foremost from genomic alterations, which cause cells to go awry. In cancer care, therapeutic decisions do not rely solely on morphology anymore, but also on the unique molecular profile of a patient’s tumour. The technology introduced today addresses this challenge by providing pathologists and oncologists with actionable information that helps them accelerate their fight against cancer.”
Jurgi Camblong CEO and Co-founder at Sophia Genetics explained “We use SOPHiA to gather all the information oncologists need in a comprehensive yet concise report. By scanning through an enormous amount of genomic data and the collective knowledge contributed to Sophia DDM®, ONCOPORTAL gives clinicians precious information about their patient tumours and the broadest treatment options available.”
Jurgi Camblong concluded, “With the ever-increasing number of tumours analysed by SOPHiA every day and an average of 10 new hospitals joining every month, we will very soon be in a position to move to real-time epidemiology – which means that we will, for example, be able to say that the cancer of patient X looks like the cancer of 10,000 other patients, among whom 10% received treatment Y and survived. By enabling the democratisation of Data-Driven Medicine, SOPHiA is a real game changer in the fight against cancer.” .
LAUSANNE, Switzerland - 13 September 2016 – Sophia Genetics, the global leader in Data-Driven Medicine (DDM), announced today that it has entered into a co-marketing agreement with Illumina, the global leader in DNA sequencing technology. The two companies will co-market their respective products and solutions to accelerate the adoption of next-generation DNA Sequencing (NGS) technologies by hospitals and laboratories for patients’ clinical diagnosis. Under the agreement, the two parties will kick-off the collaboration with joint marketing programs in EMEA.
Jurgi Camblong, CEO and co-founder of Sophia Genetics said, “We are very pleased to enter into this agreement with Illumina to speed the adoption of NGS in clinical diagnostics. Today’s agreement with Illumina underlines the value of state-of-the-art analytical solutions in routine diagnostics which truly unlock the promises of data-driven medicine for patients around the world.”
The new co-marketing arrangement will first cover the EMEA region, where Sophia Genetics and Illumina will help more hospitals and laboratories engaged in diagnostics transition to NGS and rapidly get faster, easier and more accurate results for their patients’ clinical diagnosis.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.